Glenza 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Glenza tablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA. The major metabolite of Glenza is N-desmethyl Enzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Glenza is exposed by depleting the multiplication and persuades cell lysis in prostate cancer cells.
Brand : Glenza
Ingredients : Enzalutamide
Strength : 40mg
Manufactured : Glenmark pharmaceuticals
Package : 28 Tablets
After an oral administration of Glenza 40mg tablets (160mg of dose), undergoes ADME process and exhibits activity.
The peak plasma concentration time of Glenza occurs at 1 hour with the range of 0.5 to 3 hours).
The steady state of Glenza occurs in day 28.
The volume of distribution occur after single dose of Glenza is 110L
Glenza has highly bounds to the human plasma protein with the range of 97 to 98%.
The major metabolite of Enzalutamide is N-desmethyl Enzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethyl Enzalutamide. Glenza is majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces. The terminal half life period of Glenza 40mg tablet is occurs after a single dose at 5.8days and N-desmethyl Enzalutamide is taken 7.8 to 8.6 days.
Asthenia Peripheral edema Back pain, arthralgia Musculoskeletal pain Muscular weakness Musculoskeletal stiffness Diarrhea Hot flush Hypertension Headache Dizziness Spinal cord compression Caude equine syndrome Paresthesia Mental disorders Hypoesthesia Respiratory tract infections Insomnia Anxiety Hematuria Pollakiuria Non pathologic fractures Pruritus Dry skin Epistaxis
The major adverse effect during the therapy of Glenza tablets are;
Seizure may produce during the treatment with Glenza tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition, patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.
Posterior reversible encephalopathy syndrome PRES
Patient who are all taking Glenza tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension. PRES diagnosed by MRI. If patient acquired with PRES, discontinue the Glenza therapy